Abstract:Severe combined immunodeficient (SCID) mice were injected intravenously with 5 x 10(6) primary bone marrow (BM) blasts from newly diagnosed patients with E2A-PBX1 fusion transcript positive t(1;19)(q23;p13) pre-B acute lymphoblastic leukemia (ALL). A marked variation existed in the pattern and extent of leukemic cell engraftment in SCID mice challenged with t(1;19) pre-B ALL blasts. Blasts from some patients caused disseminated leukemia that was detected by histopathology and/or flow cytometry, whereas blasts from other patients produced occult leukemia that was only detected by flow cytometry and/or polymerase-chain reaction. Notably, the ability of primary t(1;19) pre-B ALL blasts to cause disseminated leukemia in SCID mice was associated with poor prognosis. Six of six patients whose blasts caused disseminated leukemia in SCID mice relapsed at a median of 7.8 months (range: 5.7 to 25.2 months). In contrast, the remaining four patients whose blasts did not engraft or only partially engrafted remain in complete remission at 28 to 47 months. A new E2A-PBX-1 fusion transcript positive t(1;19) pre-B ALL cell line (designated LC1;19) with the composite immunophenotype CD7-CD10+CD19+CD45-HLA-DR+C mu+ was established by expanding BM blasts from a SCID mouse, which died of human t(1;19) ALL at 7 weeks after inoculation of primary leukemic blasts from a t(1;19) ALL patient. This cell line caused disseminated and invariably fatal leukemia when greater than 10(4) cells were injected intravenously into SCID mice. Total body irradiation followed by syngeneic BM transplantation (BMT) showed limited efficacy against LC1;19 leukemia in SCID mice. To our knowledge, this study is the first to (1) examine the in vivo growth of primary t(1;19) pre-B ALL blasts in SCID mice and (2) show that leukemic blasts from a majority of newly diagnosed t(1;19) pre-B ALL patients cause disseminated human leukemia in SCID mice. Our results indicate that t(1;19) pre-B ALL is biologically heterogeneous with regard to its in vivo growth pattern in SCID mice, a feature that may be predictive of prognosis. The described LC1;19 SCID mouse model may prove particularly useful for designing more effective treatment strategies against poor-prognosis t(1;19) ALL.

Spontaneous Hind Limb Paralysis Due to Acute Precursor B Cell Leukemia in RAG1-deficient Mice

Protocol to establish a stable MLL-AF9_AML mouse model.

RAG-1-deficient mice have no mature B and T lymphocytes

Improved chemotherapy modeling with RAG-based immune deficient mice

Establishment of animal model with B lineage acute leukemia in nude mice for evaluation of new therapeutic agents]

Long-term observation reveals high-frequency engraftment of human acute myeloid leukemia in immunodeficient mice

The piebald-lethal murine strain: investigation of the cause of early death

[Establishment of the Human Acute Promyelocytic Leukemia Pathological Model in the SCID Beige Mice by Using NB4 Cell Line].

Establishment of DsRed-labled leukemia mouse model

Human t(1;19)(q23;p13) pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency

[Development of Acute Promyelocytic Leukemia in PML-RARalpha Transgenic Mice]

RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement

Spontaneous Malignant T-cell Lymphoma in a Young Adult Crl:CD (SD) Rat

RAG1 and RAG2 Non-core Regions Are Implicated in Leukemogenesis and Off-target V(D)J Recombination in BCR-ABL1-driven B-cell Lineage Lym-phoblastic Leukemia

Necroptosis in Spontaneously-Mutated Hematopoietic Cells Induces Autoimmune Bone Marrow Failure in Mice

Inactivation of Pu.1 in Adult Mice Leads to the Development of Myeloid Leukemia

Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene U2af1

3223 – SUPERIORITY OF UNCONDITIONED NRG-W41 MICE EXPRESSING HUMAN IL3/GM-CSF/SCF TO ANALYZE GROWTH AND IN SITU TREATMENT OF PRIMARY HUMAN AML CELLS

A mouse model of irradiation and spleen-thymus lymphocyte infusion induced aplastic anemia

IRF4 deficiency vulnerates B-cell progeny for leukemogenesis via somatically acquired Jak3 mutations conferring IL-7 hypersensitivity

Generation of Immunodeficient Rats With Rag1 and Il2rg Gene Deletions and Human Tissue Grafting Models